Status
Conditions
Study type
Funder types
Identifiers
About
The purpose of this research study is to find out how bones are affected in children and adolescents with type 1 diabetes (T1D) as compared to children and adolescents without type 1 diabetes.
Full description
T1D is primarily associated with decrements in bone strength due to disrupted microarchitecture occurring during peak bone mass accrual, and this disruption arises from hyperglycemia and glycemic variability. Impaired bone development during this period likely predisposes to an increased fracture risk across the lifespan.
The investigators will compare baseline, 12 month and 24 month changes in High-resolution peripheral quantitative computed tomography/micro-finite element analysis (HR-pQCT/μFEA)-based estimates of bone strength and bone turnover by biochemical measurements in 40 T1D children at the onset of peak bone mineral accretion (n=40) versus sex and puberty-matched healthy controls (n=40). The investigators will determine relationships between changes in bone strength (including trabecular and cortical components) and measures of glycemic control and variability by continuous glucose monitoring (CGM).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria (T1D and Controls):
- Children within 2 years preceding the onset of the pubertal growth spurt
Inclusion Criteria (T1D participants):
- documentation of β-cell autoimmunity and need for insulin replacement
Exclusion Criteria:
Estimated glomerular filtration rate (eGFR)< 60 ml/mim
25(OH)D level < 20 ng/ml.
Celiac disease
Autoimmune thyroid disease
Addison's disease
History of pathological fractures
-- Disorders associated with altered skeletal structure or function
Bone active drugs in past year
Diabetes of other or unclear etiology
86 participants in 2 patient groups
Loading...
Central trial contact
Beatriz Omeragic Clinical Research Coordinator, BA; Rukshana Majeed, BA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal